It would seem the perfect opportunity to promote the benefits of Relenza over Tamiflu in the Australian context. 1. Significant resistance to Tamiflue in an Australian population 2. Lack of awareness among Australian GPs of Relenza benefits compared to Tamiflue 3. Opportunity to push Australian health authorities to rebalance supplies towards Relenza
But in answer to your question many if not most of us have given up on Cook ever performing his role adequately as CEO.
BTA Price at posting:
90.0¢ Sentiment: Hold Disclosure: Held
